Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2008

Open Access 01-06-2008 | Research Paper

Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma

Authors: Qiulin Liao, Liang Zhao, Xiaodong Chen, Yongjian Deng, Yanqing Ding

Published in: Clinical & Experimental Metastasis | Issue 4/2008

Login to get access

Abstract

Nasopharyngeal carcinoma (NPC), one of the most common cancers in population with Chinese or Asian progeny, poses a serious health problem for southern China. It is unfortunate that most NPC victims have had lymph node metastasis (LNM) when first diagnosed. We believe that the 2D based serum proteome analysis can be useful in discovering new biomarkers that may aid in the diagnosis and therapy of NPC patients. To filter the tumor specific antigen markers of NPC, sera from 42 healthy volunteers, 27 non-LNM NPC patients and 37 LNM NPC patients were selected for screening study using 2D combined with MS. Pretreatment strategy, including sonication, albumin and immunoglobulin G (IgG) depletion, was adopted for screening differentially expressed proteins of low abundance in serum. By 2D image analysis and MALDI-TOF-MS identification, twenty-three protein spots were differentially expressed. Three of them were further validated in the sera using enzyme-linked immunosorbent assay (ELISA). Our research demonstrates that HSP70, sICAM-1 and SAA, confirmed with ELISA at sera and immunohistochemistry, are potential NPC metastasis-specific serum biomarkers which may be of great underlying significance in clinical detection and management of NPC.
Literature
1.
Kumar S, Mahanta J (1998) Aetiology of nasopharyngeal carcinoma. A review. Indian J Cancer 35(2):47–56PubMed
2.
3.
Yang HY, Xiao ZQ, Li F (2004) Establishment of 2-dE map of human low differentiation nasopharyngeal carcinoma cell line CNE-2 proteome. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29(2):123–128PubMed
4.
Jiang P, Gan M, Huang H et al (2005) Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells. J Proteome Res 4(2):599–605PubMedCrossRef
5.
Li F, Xiao Z, Zhang P et al (2007) A reference map of human nasopharyngeal squamous carcinoma proteome. Int J Oncol 30(5):1077–1088PubMed
6.
Tan C, Li J, Wang J et al (2002) Proteomic analysis of differential protein expression in human nasopharyngeal carcinoma cells induced by NAG7 transfection. Proteomics 2(3):306–312PubMedCrossRef
7.
Sun Y, Yi H, Zhang PF et al (2007) Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 581(1):131–139PubMedCrossRef
8.
Sun D, Zhang Z, Van do N et al (2007) Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol 43(1):82–87PubMedCrossRef
9.
Doustjalali SR, Yusof R, Govindasamy GK et al (2006) Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest 53(1–2):20–28PubMedCrossRef
10.
Weinkauf M, Hiddemann W, Dreyling M (2006) Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background. Electrophoresis 27(22):4555–4558PubMedCrossRef
11.
Ramagli LS (1999) Quantifying protein in 2-D PAGE solubilization buffers. Methods Mol Biol 112:99–103PubMed
12.
Yan JX, Wait R, Berkelman T et al (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21(17):3666–3672PubMedCrossRef
13.
Jackson AM, Alexandrov AB, Gribben SC et al (1993) Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer 55(6):921–925PubMedCrossRef
14.
Santarosa M, Favaro D, Quaia M et al (1995) Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int J Cancer 62(3):271–275PubMedCrossRef
15.
Bausserman LL, Herbert PN, Rodger R et al (1984) Rapid clearance of serum amyloid A from high-density lipoproteins. Biochim Biophys Acta 792(2):186–191PubMed
16.
Raynes JG, Eagling S, McAdam KP (1991) Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol 83(3):488–491PubMedCrossRef
17.
Hunt SM, Thomas MR, Sebastian LT et al (2005) Optimal replication and the importance of experimental design for gel-based quantitative proteomics. J Proteome Res 4(3):809–819PubMedCrossRef
18.
Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845–867PubMedCrossRef
19.
Etzioni R, Urban N, Ramsey S et al (2003) The case for early detection. Nat Rev Cancer 3(4):243–252PubMedCrossRef
20.
Zhang H, Liu AY, Loriaux P et al (2007) Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 6(1):64–71PubMed
21.
Anderson NL, Polanski M, Pieper R et al (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3(4):311–326PubMedCrossRef
22.
Thadikkaran L, Siegenthaler MA, Crettaz D et al (2005) Recent advances in blood-related proteomics. Proteomics 5(12):3019–3034PubMedCrossRef
23.
Nedelkov D, Kiernan UA, Niederkofler EE et al (2005) Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 102(31):10852–10857PubMedCrossRef
24.
Cho WC, Yip TT, Yip C et al (2004) Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10(1 Pt 1):43–52PubMedCrossRef
25.
Diamandis EP (2003) Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49(8):1272–1275PubMedCrossRef
26.
Diamandis EP (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96(5):353–356PubMedCrossRef
27.
Diamandis EP (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 3(4):367–378PubMedCrossRef
28.
Putnam RW (1975) The plasma proteins. New York Academic Press
29.
Curry S (2002) Beyond expansion: structural studies on the transport roles of human serum albumin. Vox Sang 83(Suppl 1):315–319PubMed
30.
Dea MK, Hamilton-Wessler M, Ader M et al (2002) Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 51(3):762–769PubMedCrossRef
31.
32.
Quero C, Colome N, Prieto MR et al (2004) Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome studies. Proteomics 4(2):303–315PubMedCrossRef
33.
Feng JT, Liu YK, Song HY et al (2005) Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5(17):4581–4588PubMedCrossRef
34.
Rothlein R, Mainolfi EA, Czajkowski M et al (1991) A form of circulating ICAM-1 in human serum. J Immunol 147(11):3788–3793PubMed
35.
Budnik A, Grewe M, Gyufko K et al (1996) Analysis of the production of soluble ICAM-1 molecules by human cells. Exp Hematol 24(2):352–359PubMed
36.
Harning R, Mainolfi E, Bystryn JC et al (1991) Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res 51(18):5003–5005PubMed
37.
Grothey A, Heistermann P, Philippou S et al (1998) Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer 77(5):801–807PubMed
38.
Zhang GJ, Adachi I (1999) Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol 14(1):71–77PubMed
39.
Nakata B, Hori T, Sunami T et al (2006) Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 6(3):1175–1179
40.
Shimizu Y, Minemura M, Tsukishiro T et al (1995) Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 22(2):525–531PubMed
41.
Kitagawa T, Matsumoto K, Iriyama K (1998) Serum cell adhesion molecules in patients with colorectal cancer. Surg Today 28(3):262–267PubMedCrossRef
42.
Yoo NC, Chung HC, Chung HC et al (1998) Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J 39(1):27–36PubMed
43.
Becker JC, Termeer C, Schmidt RE et al (1993) Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 151(12):7224–7232PubMed
44.
d’Eril GM, Anesi A, Maggiore M et al (2001) Biological variation of serum amyloid A in healthy subjects. Clin Chem 47(8):1498–1499PubMed
45.
Kimura M, Tomita Y, Imai T et al (2001) Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 92(8):2072–2075PubMedCrossRef
46.
Glojnaric I, Casl MT, Simic D et al (2001) Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 39(2):129–133PubMedCrossRef
47.
Biran H, Friedman N, Neumann L et al (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39(7):794–797PubMedCrossRef
48.
Benson MD, Cohen AS (1979) Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases. Arthritis Rheum 22(1):36–42PubMedCrossRef
49.
Diamandis EP (2004) Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin Cancer Res 10(15):5293; author reply-4
50.
Urieli-Shoval S, Cohen P, Eisenberg S et al (1998) Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 46(12):1377–1384PubMed
51.
52.
Subjeck JR, Shyy TT (1986) Stress protein systems of mammalian cells. Am J Physiol 250(1 Pt 1):C1–C17PubMed
53.
Barnes JA, Dix DJ, Collins BW et al (2001) Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress Chaperones 6(4):316–325PubMedCrossRef
54.
Ravagnan L, Gurbuxani S, Susin SA et al (2001) Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 3(9):839–843PubMedCrossRef
55.
Clark PR, Menoret A (2001) The inducible Hsp70 as a marker of tumor immunogenicity. Cell Stress Chaperones 6(2):121–125PubMedCrossRef
56.
Milicevic ZT, Petkovic MZ, Drndarevic NC et al (2007) Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarcinoma–immunohistochemistry and Western blot analysis. Neoplasma 54(1):37–45PubMed
57.
Lazaris A, Chatzigianni EB, Panoussopoulos D et al (1997) Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 43(1):43–51PubMedCrossRef
58.
Torronteguy C, Frasson A, Zerwes F et al (2006) Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors. Cell Stress Chaperones 11(1):34–43PubMedCrossRef
59.
Abe M, Manola JB, Oh WK et al (2004) Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer 3(1):49–53PubMed
60.
Chuma M, Sakamoto M, Yamazaki K et al (2003) Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37(1):198–207PubMedCrossRef
61.
Lazaris AC, Theodoropoulos GE, Aroni K et al (1995) Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 426(5):461–467PubMedCrossRef
62.
Kaur J, Das SN, Srivastava A et al (1998) Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features. Oral Oncol 34(2):93–98PubMedCrossRef
63.
Volm M, Koomagi R, Mattern J et al (2002) Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases. Clin Exp Metastasis 19(5):385–390PubMedCrossRef
64.
Mambula SS, Calderwood SK (2006) Heat induced release of Hsp70 from prostate carcinoma cells involves both active secretion and passive release from necrotic cells. Int J Hyperthermia 22(7):575–585PubMedCrossRef
65.
Mambula SS, Calderwood SK (2006) Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 177(11):7849–7857PubMed
Metadata
Title
Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma
Authors
Qiulin Liao
Liang Zhao
Xiaodong Chen
Yongjian Deng
Yanqing Ding
Publication date
01-06-2008
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9152-8

Other articles of this Issue 4/2008

Clinical & Experimental Metastasis 4/2008 Go to the issue

Research Paper

Bisphosphonates for bone metastatic disease from breast cancer—clinical practice in the Czech Republic

Review Paper

Stepping out of the flow: capillary extravasation in cancer metastasis

Research paper

Organ selectivity in metastasis: regulation by chemokines and their receptors

Research Paper

The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival

Research Paper

First surgical tumour reduction of peritoneal surface malignancy in a rat’s model

Research Paper

Dissociated invasively growing cancer cells with NF-kappaB/p65 positivity after radiotherapy: a new marker for worse clinical outcome in rectal cancer? Preliminary data
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits